AACR Awards & Honors to Memorial Sloan Kettering Scientists

MSK’s Kenneth Offit, MD, MPH, and Ross L. Levine, MD, Have Been Elected As Fellows of the AACR Academy

MSK’s Kenneth Offit, MD, MPH, and Ross L. Levine, MD, have been elected as Fellows of the AACR Academy, one of the highest honors bestowed by AACR. Election to the AACR Academy recognizes extraordinary scientists whose work has made a profound and lasting impact on cancer research. Drs. Offit and Levine join 18 Fellows of the AACR Academy from MSK previously elected over the course of the program’s 13-year history.

Dr. Offit was elected for trailblazing research in hereditary cancer genetics, including the discovery of BRCA2 mutations in Ashkenazi Jewish populations, which led to the first genome-wide association study linking BRCA2 to breast cancer risk. His work further identified recurrent APC, BLM, and MSH2 gene mutations in colon cancer, helping to shape modern approaches to inherited cancer risk stratification, prevention, and early detection.

Dr. Levine was elected for groundbreaking contributions to defining the molecular biology of myeloid malignancies, including the discovery of key driver mutations, characterization of oncogenic signaling pathways such as JAK-STAT, and investigation of epigenetic mechanisms that influence disease progression in myeloproliferative neoplasms (MPN) and acute myeloid leukemia (AML).

Fellows are nominated and elected through a rigorous, multistep, peer-reviewed process that evaluates scientific achievements and contributions to the global cancer research community. Only individuals whose work has made a profound and lasting impact on cancer research are selected. The Class of 2026 includes 24 newly elected Fellows, bringing the total membership of the AACR Academy to 399.

MSK’s Luis A. Diaz Jr., MD, FAACR Awarded the AACR-Joseph H. Burchenal Award for Outstanding Achievement in Clinical Cancer Research

MSK’s Luis A. Diaz Jr., MD, was awarded the AACR-Joseph H. Burchenal Award for Outstanding Achievement in Clinical Cancer Research. This award recognizes outstanding achievements in clinical cancer research. Dr. Diaz is being recognized for his pioneering discoveries that have transformed cancer treatment options such as biomarker-driven immunotherapies and for demonstrating that tumors with mismatch repair deficiencies and microsatellite instability are highly responsive to immune checkpoint blockade. Dr. Diaz has also advanced the use of circulating tumor DNA (ctDNA) to detect minimal residual disease and led clinical trials of PD-1 blockade in mismatch repair-deficient cancers, including rectal cancer studies that featured complete responses with immunotherapy alone. His work established defective DNA repair as a predictive biomarker for immunotherapy response and enabled the first tissue-agnostic approval of a cancer therapy based on a molecular signature. His award lecture will be held on Monday, April 20, 2026, at 5:00 p.m. PT. 

MSK’s Ross L. Levine, MD, Elected to AACR Board of Directors

Ross L. Levine, MD, Chief Scientific Officer of MSK, was also elected to the AACR Board of Directors, one of five individuals chosen to serve in the 2026-2029 term.

[News release]